Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Medical Sciences Division welcomes Steve Bates, CEO of the UK Bioindustry Association, as a Royal Society Entrepreneur in Residence. Steve Bates will be working very closely with our Translational Research Office and key teams across the University of Oxford's innovation ecosystem.

Steve Bates alongside the Royal Society logo

Steve will lead an initiative to capture how academic institutions can deliver lifesaving technologies, incorporating learnings from the Covid era. In the recent years, we have seen the Oxford – Astra Zeneca Covid 19 vaccine, and other technologies such as OxVent, being developed and delivered to patients in a record time of one year, which would have been unimaginable prior to the Covid times.

Steve will work with academic teams and organisations to learn from the Covid response and investigate how we apply these learnings for future endeavours, facilitating a sustainable and perennial ‘fast-track route to innovation’ in academic organisations.  

In his role, Steve will:

  • Investigate and understand which potential organisational barriers exists but could be bypassed to respond rapidly to unmet needs
  • Identify measures and implementable changes in procedures across the university standard business practices.  
  • Ensure that the cultural and procedural shockwaves from the Covid19 programmes impacts organisations to be better equipped to support, facilitate, and implement entrepreneurial success.  

Find out more about the Entrepreneur in Residence scheme

About Steve Bates

Steve Bates has been the CEO of the UK Bioindustry Association since 2012, representing the UK Life Sciences Industry, as it developed into a key global innovation cluster for the biotechnology industry. Steve sits on the UK Government’s Life Sciences Council (alongside Professor Sir John Bell) and Life Sciences Industrial Strategy Implementation Board, and chairs the Global International Council of Biotech Associations. He worked on advocating for the UKRI Biomedical Catalyst scheme, supporting translational research and bridging the gap between early stage research and industry in the U.K. In 2020, Steve Bates was part of the UK Government Covid19 Vaccine Taskforce Steering Group, supporting the delivery of the UK vaccine through the pandemic. He was awarded an OBE for services to innovation in 2017 and made a fellow of the Academy of Medical Sciences in 2021.

About the Royal Society Entrepreneur in Residence (EiR) Scheme

The Royal Society Entrepreneur in Residence (EiR) scheme, part of the Science, Industry and Translation programme, aims to increase the knowledge and awareness in UK universities of cutting edge industrial science, research and innovation. The successful applicants are funded to spend 20% of their time over two years with their host university and collaborators, sharing their experiences to help mentor and support students and academics. The scheme has now funded 49 placements in 29 universities across the UK since its inception in 2018.

Read more on the Royal Society website.

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.